摘要
目的:研究骨髓增生异常综合征(MDS)细胞周期与化疗疗效之间的关联性。方法:采用流式细胞术分析27例化疗前中高危MDS患者细胞周期;应用地西他滨对MDS患者进行16周的化疗,根据IWG疗效标准对化疗疗效进行评估。结果:应用地西他滨治疗之后,17例患者病情稳定(SD),10例患者病情恶化(PD)。SD组的G0/G1期的比例为(96.349±6.535)%,PD组的G0/G1期的比例为(97.490±1.861)%,P值为0.5871,两组间差异无统计学意义(P>0.05);在S期,SD组的比例为(3.332±5.895)%,PD组为(2.335±1.904)%,两组间差异无统计学意义(P>0.05);在G2/M期,SD组的比例为(0.318±0.716)%,PD组为(0.155±0.219)%,两组间差异无统计学意义(P>0.05)。结论:细胞周期与地西他滨化疗疗效之间没有相关性,不能作为化疗疗效的预测指标。
Objective:To investigate the relationship between myelodysplastic syndromes(MDS)cell cycle and chemotherapy efficacy of decitabine.Methods:The cell cycle of 27 patients with MDS before chemotherapy was analyzed using flow cytometry.MDS patients were treated with decitabine for 16 weeks,and the efficacy of chemotherapy was subsequently evaluated using IWG criteria.Results:In the 27 patients undergoing chemotherapy,17 patients attained stable disease(SD)and 10 patients suffered from progress disease(PD).Flow cytometry showed that the ratio of G0/G1 phase in the SD group was(96.349±6.535)%,while that in the PD group was(97.490±1.861)%(P>0.05).In S phase,the proportion of SD group was(3.332±5.895)%,and that of PD group was(2.335±1.904)%(P>0.05).In G2/M phase,the proportion of SD patients was(0.318±0.716)%,while PD group was(0.155±0.219)%(P>0.05).Conclusion:There is no correlation between cell cycle and chemotherapy efficacy of decitabine,indicating that it cannot be used as a predictor of chemotherapy efficacy.
作者
詹扬
王丽红
钟龙
陆佳
徐海涛
杨达天
陈丹桂
陈非
姚福生
ZHAN Yang;WANG Li-hong;ZHONG Long(Anqing Municipal Hospital Affiliated to Anhui Medical University,Anqing 240000,Anhui)
出处
《安徽医专学报》
2021年第6期30-32,共3页
Journal of Anhui Medical College
基金
安徽医科大学2019年度校科研基金项目(自然科学)立项(编号:2019xkj231)。
